Dr. Lerner on the pivotal OLYMPUS trial of Jelmyto in UTUC
“Of the 42 patients who achieved a complete response, 41 of those were evaluable for duration of response, which was the focus of the manuscript that was just published last month,” says Seth P. Lerner, MD.
In this video, Seth P. Lerner, MD, discusses the background of the OLYMPUS trial, which has now released its final report. The phase 3 trial supported the FDA approval of mitomycin-containing reverse thermal gel (UGN-101; Jelmyto) for the treatment of patients with low-grade upper tract urothelial cancer.
Lerner is a professor in the Scott Department of Urology and Beth and Dave Swalm Chair in urologic oncology at the Baylor College of Medicine Medical Center in Houston, Texas.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
